Gamida Cell price target lowered to $5 from $11 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Gamida Cell to $5 from $11 and keeps a Buy rating on the shares post the Q3 report. Although Gamida Cell’s launch performance has exceeded the company’s expectations, the company is experiencing challenges associated with launch of a novel cell therapy, the analyst tells investors in a research note. The firm says its initial Omisirge projections were aggressive.